Managed Access Program for Belantamab Mafodotin in Combination With Either Bortezomib/Dexamethasone or Pomalidomide/Dexamethasone in Patients With Multiple Myeloma Previously Treated With at Least 1 Prior Line of Therapy
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Belantamab mafodotin (Primary)
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 09 Mar 2021 Status changed from recruiting to completed.
- 12 Dec 2018 New trial record